Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Document Details

Document Type
Pub Defense Publication
Publication Date
May 01, 2020
Source ID
10.1016/j.annonc.2020.02.008

Entities

People

  • A.d. D’andrea
  • A.g. Waks
  • B. Kochupurakkal
  • C.e. Dunn
  • Daehyun Kim
  • E.p. Winer
  • G.i. Shapiro
  • I.e. Krop
  • J. Buendia Buendia
  • J. Geradts
  • K. Helvie
  • L. Marini
  • M.e. Hughes
  • M.r. Lloyd
  • N. Wagle
  • N.u. Lin
  • O. Cohen
  • P. Lorusso
  • S. Wander
  • S.m. Tolaney
  • S.p. Ivy
  • S.s. Freeman
  • Steven J. Isakoff
  • U. Matulonis
  • V.a. Adalsteinsson

Organizations

  • American Society of Clinical Oncology
  • Breast Cancer Alliance
  • Dana Farber Harvard Cancer Center
  • Dana–Farber Cancer Institute
  • National Cancer Institute
  • National Comprehensive Cancer Network
  • National Institutes of Health
  • Pfizer
  • The Breast Cancer Research Foundation
  • United States Department of Defense
  • V Foundation for Cancer Research
  • Yale Cancer Center